Title
Synthetic biology for next-generation medicine
Description
Synthetic biology is reshaping medicine by making it possible to design, build, and manufacture biological systems with increasing precision. This Special Issue brings together advances spanning the full innovation pathway, from enabling technologies—genome engineering, synthetic gene circuits, artificial intelligence, automation, and cell-free platforms—to new concepts in drug discovery and therapeutic programming.
A particular focus will be placed on green and intelligent biomanufacturing strategies for high-value pharmaceuticals and living medicines, with attention to scalability, sustainability, process control, and product quality. In parallel, the issue will examine emerging diagnostic and therapeutic modalities, including programmable biosensors, engineered cells and microbes, precision delivery systems, and closed-loop interventions that sense, compute, and respond within disease-relevant contexts.
We welcome original research articles, reviews, and perspectives that report transformative technologies, mechanistic insights, translational frameworks, or clinically relevant evidence. Contributions should advance the role of synthetic biology in personalized and precision medicine while clarifying the design principles, manufacturing constraints, and validation pathways needed for future clinical impact.
Topics
Powering synthetic biology with new technologies
Reinventing drug discovery through synthetic biology
Advancing green biomanufacturing for high-value medicines
Transforming diagnostics and therapeutics for precision medicine
Content types
Article, review, perspective, letter, etc.
APCs
Article Publishing Charges (APCs) will be waived by 2027.
Deadline
May 31, 2027
Guest editors:
Chenli Liu
Distinguished Professor
Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, China
Research area: Quantitative and clinical synthetic biology, engineered bacterial therapeutics for cancer
Email: cl.liu@siat.ac.cn
Junjun Chu
Professor
Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, China
Research area: T cell biology and T cell-based synthetic immunotherapy
Email: jj.chu@siat.ac.cn
Ju Cui
Professor
National Health Commission (NHC) Key Laboratory of Geriatrics, Beijing Hospital, National Center for Gerontology, China
Research area: Mechanisms of aging and cancer, biomarkers and quantitative assessment of aging, and population-based health research
Email: cuiju4366@bjhmoh.cn
Haiyun Gan
Professor
Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, China
Research area: Epigenetics and synthetic Biology
Email:hy.gan@siat.ac.cn
Tian Ma
Associate Professor
Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, China
Research area: Synthetic biology and metabolic engineering
Email: tian.ma@siat.ac.cn
Submission guidelines
Please submit your paper through our online submission system. All papers will be peer-reviewed. The submission deadline is May 31, 2027. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together. Research articles, review articles, letters, commentaries as well as perspectives are invited.
hLife adopts format-free submission. Format-free submission means that, provided you include everything necessary for review and use a consistent citation format, you can submit your paper without needing to worry about formatting your manuscript to meet hLife’s requirements.
Please state in the cover letter that your submission is for the section “Synthetic biology for next-generation medicine”. Article Publishing Charges (APCs) for received papers of hLife will be waived by 2027.
Submission website
https://www.editorialmanager.com/hlife
转载本文请联系原作者获取授权，同时请注明本文来自闫群科学网博客。
链接地址：https://wap.sciencenet.cn/blog-3552961-1549801.html?mobile=1
收藏
